Ruth Ladenstein1, Ulrike Pötschger2, Dominique Valteau-Couanet3, Roberto Luksch4, Victoria Castel5, Isaac Yaniv6, Genevieve Laureys7, Penelope Brock8, Jean Marie Michon9, Cormac Owens10, Toby Trahair11, Godfrey Chi Fung Chan12, Ellen Ruud13, Henrik Schroeder14, Maja Beck Popovic15, Guenter Schreier16, Hans Loibner17, Peter Ambros18, Keith Holmes19, Maria Rita Castellani4, Mark N Gaze20, Alberto Garaventa21, Andrew D J Pearson22, Holger N Lode23. 1. St Anna Children's Hospital, Vienna, Austria; Department for Studies and Statistics and Integrated Research, Vienna, Austria; Children's Cancer Research Institute, Vienna, Austria. Electronic address: ruth.ladenstein@ccri.at. 2. Department for Studies and Statistics and Integrated Research, Vienna, Austria; Children's Cancer Research Institute, Vienna, Austria. 3. Children and Adolescent Oncology Department, Gustave Roussy, Paris-Sud University, Paris, France. 4. Department di Ematologica e Onco-Ematologica, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. 5. Pediatric Oncology Unit, Hospital Universitario y Politecnico La Fe, Valencia, Spain. 6. Pediatric Oncology Unit, Schneider Children's Medical Center of Israel, Sackler Faculty of Medicine Tel Aviv University, Petach Tikvah, Israel. 7. Department of Pediatric Hematology/Oncology and Stem Cell Transplantation University Hospital Ghent, Ghent, Belgium. 8. Department of Pediatric Oncology, Great Ormond Street Hospital, London, UK. 9. Children, Adolescent and Young Adults Department, Institut Curie, Paris, France. 10. Department of Haemato-Oncology, Our Lady's Children's Hospital, Dublin, Ireland. 11. Kids Cancer Centre, Sydney Children's Hospital, Randwick, NSW, Australia. 12. Department of Paediatrics & Adolescent Medicine, Queen Mary Hospital, Hong Kong. 13. Department of Paediatric Medicine, Rikshospitalet, Oslo, Norway. 14. Department of Paediatrics, University Hospital of Aarhus, Aarhus, Denmark. 15. Department of Paediatrics and Paediatric Surgery, Paediatric Haematology Oncology Unit, University Hospital Lausanne, Switzerland. 16. Centre for Health and Bioresources, AIT Austrian Institute of Technology GmbH, Graz, Austria. 17. Apeiron Biologics AG, Vienna, Austria. 18. Department of Biology, Vienna, Austria; Children's Cancer Research Institute, Vienna, Austria. 19. Department of Paediatric Surgery, St George's Hospital, London, UK. 20. Department of Oncology, University College London Hospitals NHS Foundation Trust, National Institute for Health Research University College London Hospitals Biomedical Research Centre, London, UK. 21. Oncology Unit, Istituto Giannina Gaslini, Genoa, Italy. 22. Paediatric and Adolescent Drug Development Team, Oak Centre for Children and Young People, Institute of Cancer Research, Royal Marsden Hospital, Sutton, UK. 23. Paediatric Haematology-Oncology Department, University Medicine Greifswald, Greifswald, Germany.
Abstract
BACKGROUND: Immunotherapy with the chimeric anti-GD2 monoclonal antibody dinutuximab, combined with alternating granulocyte-macrophage colony-stimulating factor and intravenous interleukin-2 (IL-2), improves survival in patients with high-risk neuroblastoma. We aimed to assess event-free survival after treatment with ch14.18/CHO (dinutuximab beta) and subcutaneous IL-2, compared with dinutuximab beta alone in children and young people with high-risk neuroblastoma. METHODS: We did an international, open-label, phase 3, randomised, controlled trial in patients with high-risk neuroblastoma at 104 institutions in 12 countries. Eligible patients were aged 1-20 years and had MYCN-amplified neuroblastoma with stages 2, 3, or 4S, or stage 4 neuroblastoma of any MYCN status, according to the International Neuroblastoma Staging System. Patients were eligible if they had been enrolled at diagnosis in the HR-NBL1/SIOPEN trial, had completed the multidrug induction regimen (cisplatin, carboplatin, cyclophosphamide, vincristine, and etoposide, with or without topotecan, vincristine, and doxorubicin), had achieved a disease response that fulfilled prespecified criteria, had received high-dose therapy (busulfan and melphalan or carboplatin, etoposide, and melphalan) and had received radiotherapy to the primary tumour site. In this component of the trial, patients were randomly assigned (1:1) to receive dinutuximab beta (20 mg/m2 per day as an 8 h infusion for 5 consecutive days) or dinutuximab beta plus subcutaneous IL-2 (6 × 106 IU/m2 per day on days 1-5 and days 8-12 of each cycle) with the minimisation method to balance randomisation for national groups and type of high-dose therapy. All participants received oral isotretinoin (160 mg/m2 per day for 2 weeks) before the first immunotherapy cycle and after each immunotherapy cycle, for six cycles. The primary endpoint was 3-year event-free survival, analysed by intention to treat. This trial was registered with ClinicalTrials.gov, number NCT01704716, and EudraCT, number 2006-001489-17, and recruitment to this randomisation is closed. FINDINGS: Between Oct 22, 2009, and Aug 12, 2013, 422 patients were eligible to participate in the immunotherapy randomisation, of whom 406 (96%) were randomly assigned to a treatment group (n=200 to dinutuximab beta and n=206 to dinutuximab beta with subcutaneous IL-2). Median follow-up was 4·7 years (IQR 3·9-5·3). Because of toxicity, 117 (62%) of 188 patients assigned to dinutuximab beta and subcutaneous IL-2 received their allocated treatment, by contrast with 160 (87%) of 183 patients who received dinutuximab beta alone (p<0·0001). 3-year event-free survival was 56% (95% CI 49-63) with dinutuximab beta (83 patients had an event) and 60% (53-66) with dinutuximab beta and subcutaneous IL-2 (80 patients had an event; p=0·76). Four patients died of toxicity (n=2 in each group); one patient in each group while receiving immunotherapy (n=1 congestive heart failure and pulmonary hypertension due to capillary leak syndrome; n=1 infection-related acute respiratory distress syndrome), and one patient in each group after five cycles of immunotherapy (n=1 fungal infection and multi-organ failure; n=1 pulmonary fibrosis). The most common grade 3-4 adverse events were hypersensitivity reactions (19 [10%] of 185 patients in the dinutuximab beta group vs 39 [20%] of 191 patients in the dinutuximab plus subcutaneous IL-2 group), capillary leak (five [4%] of 119 vs 19 [15%] of 125), fever (25 [14%] of 185 vs 76 [40%] of 190), infection (47 [25%] of 185 vs 64 [33%] of 191), immunotherapy-related pain (19 [16%] of 122 vs 32 [26%] of 124), and impaired general condition (30 [16%] of 185 vs 78 [41%] of 192). INTERPRETATION: There is no evidence that addition of subcutaneous IL-2 to immunotherapy with dinutuximab beta, given as an 8 h infusion, improved outcomes in patients with high-risk neuroblastoma who had responded to standard induction and consolidation treatment. Subcutaneous IL-2 with dinutuximab beta was associated with greater toxicity than dinutuximab beta alone. Dinutuximab beta and isotretinoin without subcutaneous IL-2 should thus be considered the standard of care until results of ongoing randomised trials using a modified schedule of dinutuximab beta and subcutaneous IL-2 are available. FUNDING: European Commission 5th Frame Work Grant, St. Anna Kinderkrebsforschung, Fondation ARC pour la recherche sur le Cancer.
BACKGROUND: Immunotherapy with the chimeric anti-GD2 monoclonal antibody dinutuximab, combined with alternating granulocyte-macrophage colony-stimulating factor and intravenous interleukin-2 (IL-2), improves survival in patients with high-risk neuroblastoma. We aimed to assess event-free survival after treatment with ch14.18/CHO (dinutuximab beta) and subcutaneous IL-2, compared with dinutuximab beta alone in children and young people with high-risk neuroblastoma. METHODS: We did an international, open-label, phase 3, randomised, controlled trial in patients with high-risk neuroblastoma at 104 institutions in 12 countries. Eligible patients were aged 1-20 years and had MYCN-amplified neuroblastoma with stages 2, 3, or 4S, or stage 4 neuroblastoma of any MYCN status, according to the International Neuroblastoma Staging System. Patients were eligible if they had been enrolled at diagnosis in the HR-NBL1/SIOPEN trial, had completed the multidrug induction regimen (cisplatin, carboplatin, cyclophosphamide, vincristine, and etoposide, with or without topotecan, vincristine, and doxorubicin), had achieved a disease response that fulfilled prespecified criteria, had received high-dose therapy (busulfan and melphalan or carboplatin, etoposide, and melphalan) and had received radiotherapy to the primary tumour site. In this component of the trial, patients were randomly assigned (1:1) to receive dinutuximab beta (20 mg/m2 per day as an 8 h infusion for 5 consecutive days) or dinutuximab beta plus subcutaneous IL-2 (6 × 106 IU/m2 per day on days 1-5 and days 8-12 of each cycle) with the minimisation method to balance randomisation for national groups and type of high-dose therapy. All participants received oral isotretinoin (160 mg/m2 per day for 2 weeks) before the first immunotherapy cycle and after each immunotherapy cycle, for six cycles. The primary endpoint was 3-year event-free survival, analysed by intention to treat. This trial was registered with ClinicalTrials.gov, number NCT01704716, and EudraCT, number 2006-001489-17, and recruitment to this randomisation is closed. FINDINGS: Between Oct 22, 2009, and Aug 12, 2013, 422 patients were eligible to participate in the immunotherapy randomisation, of whom 406 (96%) were randomly assigned to a treatment group (n=200 to dinutuximab beta and n=206 to dinutuximab beta with subcutaneous IL-2). Median follow-up was 4·7 years (IQR 3·9-5·3). Because of toxicity, 117 (62%) of 188 patients assigned to dinutuximab beta and subcutaneous IL-2 received their allocated treatment, by contrast with 160 (87%) of 183 patients who received dinutuximab beta alone (p<0·0001). 3-year event-free survival was 56% (95% CI 49-63) with dinutuximab beta (83 patients had an event) and 60% (53-66) with dinutuximab beta and subcutaneous IL-2 (80 patients had an event; p=0·76). Four patients died of toxicity (n=2 in each group); one patient in each group while receiving immunotherapy (n=1 congestive heart failure and pulmonary hypertension due to capillary leak syndrome; n=1 infection-related acute respiratory distress syndrome), and one patient in each group after five cycles of immunotherapy (n=1 fungal infection and multi-organ failure; n=1 pulmonary fibrosis). The most common grade 3-4 adverse events were hypersensitivity reactions (19 [10%] of 185 patients in the dinutuximab beta group vs 39 [20%] of 191 patients in the dinutuximab plus subcutaneous IL-2 group), capillary leak (five [4%] of 119 vs 19 [15%] of 125), fever (25 [14%] of 185 vs 76 [40%] of 190), infection (47 [25%] of 185 vs 64 [33%] of 191), immunotherapy-related pain (19 [16%] of 122 vs 32 [26%] of 124), and impaired general condition (30 [16%] of 185 vs 78 [41%] of 192). INTERPRETATION: There is no evidence that addition of subcutaneous IL-2 to immunotherapy with dinutuximab beta, given as an 8 h infusion, improved outcomes in patients with high-risk neuroblastoma who had responded to standard induction and consolidation treatment. Subcutaneous IL-2 with dinutuximab beta was associated with greater toxicity than dinutuximab beta alone. Dinutuximab beta and isotretinoin without subcutaneous IL-2 should thus be considered the standard of care until results of ongoing randomised trials using a modified schedule of dinutuximab beta and subcutaneous IL-2 are available. FUNDING: European Commission 5th Frame Work Grant, St. Anna Kinderkrebsforschung, Fondation ARC pour la recherche sur le Cancer.
Authors: Rajen Mody; Alice L Yu; Arlene Naranjo; Fan F Zhang; Wendy B London; Barry L Shulkin; Marguerite T Parisi; Sabah-E-Noor Servaes; Mitchell B Diccianni; Jacquelyn A Hank; Mildred Felder; Jennifer Birstler; Paul M Sondel; Shahab Asgharzadeh; Julia Glade-Bender; Howard Katzenstein; John M Maris; Julie R Park; Rochelle Bagatell Journal: J Clin Oncol Date: 2020-04-28 Impact factor: 44.544
Authors: Luis Martí-Bonmatí; Ángel Alberich-Bayarri; Ruth Ladenstein; Ignacio Blanquer; J Damian Segrelles; Leonor Cerdá-Alberich; Polyxeni Gkontra; Barbara Hero; J M García-Aznar; Daniel Keim; Wolfgang Jentner; Karine Seymour; Ana Jiménez-Pastor; Ismael González-Valverde; Blanca Martínez de Las Heras; Samira Essiaf; Dawn Walker; Michel Rochette; Marian Bubak; Jordi Mestres; Marco Viceconti; Gracia Martí-Besa; Adela Cañete; Paul Richmond; Kenneth Y Wertheim; Tomasz Gubala; Marek Kasztelnik; Jan Meizner; Piotr Nowakowski; Salvador Gilpérez; Amelia Suárez; Mario Aznar; Giuliana Restante; Emanuele Neri Journal: Eur Radiol Exp Date: 2020-04-03
Authors: Mireille Vankemmelbeke; Richard S McIntosh; Jia Xin Chua; Thomas Kirk; Ian Daniels; Marilena Patsalidou; Robert Moss; Tina Parsons; David Scott; Gemma Harris; Judith M Ramage; Ian Spendlove; Lindy G Durrant Journal: Cancer Res Date: 2020-06-12 Impact factor: 12.701
Authors: Rosa Nguyen; Ardiana Moustaki; Jacqueline L Norrie; Shantel Brown; Walter J Akers; Abbas Shirinifard; Michael A Dyer Journal: Clin Cancer Res Date: 2019-08-27 Impact factor: 12.531